Header Logo

Lauren E Dockery

TitleProf,Asst
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentGynecologic Oncology
AddressSOCC 5050
800 NE 10th St
Oklahoma City OK 73104
Phone405/271-8001 ext 48893
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Abdoli N, Zhang K, Gilley P, Chen X, Sadri Y, Thai T, Dockery L, Moore K, Mannel R, Qiu Y. Evaluating the Effectiveness of 2D and 3D CT Image Features for Predicting Tumor Response to Chemotherapy. Bioengineering (Basel). 2023 Nov 20; 10(11). PMID: 38002458; PMCID: PMC10669238.
      Citations:    
    2. Zhang K, Abdoli N, Gilley P, Sadri Y, Chen X, Thai TC, Dockery L, Moore K, Mannel RS, Qiu Y. Developing a Novel Image Marker to Predict the Responses of Neoadjuvant Chemotherapy (NACT) for Ovarian Cancer Patients. ArXiv. 2023 Sep 13. PMID: 37744460; PMCID: PMC10516116.
      Citations:    
    3. Dey DK, Krause D, Rai R, Choudhary S, Dockery LE, Chandra V. The role and participation of immune cells in the endometrial tumor microenvironment. Pharmacol Ther. 2023 Sep 09; 251:108526. PMID: 37690483.
      Citations: 1     Fields:    Translation:Humans
    4. Ade CJ, Dockery L, Walter AC, Benbrook DM, Vesely SK, Hammond ST, Moore KN, Holman LL. Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study. Nutr Cancer. 2023; 75(2):662-669. PMID: 36495155; PMCID: PMC10127353.
      Citations:    Fields:    Translation:Humans
    5. Jackson CG, Moore KN, Cantrell L, Erickson BK, Duska LR, Richardson DL, Landrum LM, Holman LL, Walker JL, Mannel RS, Moxley KM, Queimado L, Cohoon A, Ding K, Dockery LE. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49. PMID: 35491267.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    6. Dockery LE, Soper JT. Vulvar Intraepithelial Neoplasia: A Review of the Disease and Current Management. Obstet Gynecol Surv. 2021 Jan; 76(1):55-62. PMID: 33506879.
      Citations: 2     Fields:    Translation:HumansCells
    7. Rimel BJ, Dockery L, Randall LM, Moore K. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711. PMID: 32880196.
      Citations:    Fields:    Translation:Humans
    8. Dockery LE, Rubenstein AR, Ding K, Mashburn SG, Burkett WC, Davis AM, Doo DW, Arend RC, Moore KN, Gunderson CC. Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 11; 155(2):201-206. PMID: 31522837.
      Citations: 2     Fields:    Translation:Humans
    9. Dockery LE, Motwani A, Ding K, Doescher M, Dvorak JD, Moore KN, Holman LL. Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough. Gynecol Oncol. 2018 04; 149(1):89-92. PMID: 29605056.
      Citations: 6     Fields:    Translation:Humans
    10. Dockery LE, Tew WP, Ding K, Moore KN. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513. PMID: 29037805.
      Citations: 15     Fields:    Translation:Humans
    11. Dockery LE, Gunderson CC, Moore KN. Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther. 2017; 10:3029-3037. PMID: 28790837.
      Citations: 23     
    Dockery's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (60)
    Explore
    _
    Co-Authors (16)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _